Is Buying Aradigm Corporation (NASDAQ:ARDM), Having Lower Short Interest a Winning Strategy?

September 16, 2018 - By Andrea Pope

Investors sentiment decreased to 0.5 in 2018 Q2. Its down 1.50, from 2 in 2018Q1. It dropped, as 2 investors sold Aradigm Corporation shares while 4 reduced holdings. 1 funds opened positions while 2 raised stakes. 4.08 million shares or 1.11% less from 4.12 million shares in 2018Q1 were reported.
Deutsche Bancorp Ag has invested 0% in Aradigm Corporation (NASDAQ:ARDM). Susquehanna Interest Gru Llp accumulated 33,408 shares. Geode Capital Limited Liability invested in 63,010 shares. Art Advisors Lc holds 0% in Aradigm Corporation (NASDAQ:ARDM) or 11,994 shares. Fmr Llc has 0% invested in Aradigm Corporation (NASDAQ:ARDM) for 168,740 shares. Royal Bank & Trust Of Canada has invested 0% of its portfolio in Aradigm Corporation (NASDAQ:ARDM). Spark Mgmt stated it has 0% in Aradigm Corporation (NASDAQ:ARDM). Morgan Stanley stated it has 3,000 shares or 0% of all its holdings. First Eagle Inv Mgmt Ltd Liability Co holds 3.38M shares or 0.01% of its portfolio. Blackrock holds 0% or 4,866 shares in its portfolio. Vanguard Group has 362,098 shares. Northern Corporation has invested 0% of its portfolio in Aradigm Corporation (NASDAQ:ARDM).

The stock of Aradigm Corporation (NASDAQ:ARDM) registered a decrease of 24% in short interest. ARDM’s total short interest was 198,900 shares in September as published by FINRA. Its down 24% from 261,700 shares, reported previously. With 19,500 shares average volume, it will take short sellers 10 days to cover their ARDM’s short positions. The short interest to Aradigm Corporation’s float is 2.1%.

The stock decreased 3.10% or $0.04 during the last trading session, reaching $1.25. About 7,330 shares traded. Aradigm Corporation (NASDAQ:ARDM) has declined 3.70% since September 16, 2017 and is downtrending. It has underperformed by 19.32% the S&P500.

Aradigm Corporation, a specialty pharmaceutical company, focuses on the development and commercialization of drugs for the prevention and treatment of severe respiratory diseases. The company has market cap of $18.98 million. The companyÂ’s lead development candidates are proprietary formulations of the potent antibiotic ciprofloxacin, including Linhaliq and Lipoquin (ARD-3100) that are delivered by inhalation for the management of infections associated with severe respiratory diseases, including non-cystic fibrosis bronchiectasis and cystic fibrosis. It currently has negative earnings. It is also developing inhaled ciprofloxacin formulations for treatment of patients with cystic fibrosis and non-tuberculous mycobacteria, as well as the prevention and treatment of high threat and bioterrorism infections, such as inhaled tularemia, pneumonic plague, melioidosis, Q fever, and inhaled anthrax.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.